CURRICULUM VITAE

Daniel A. Pollyea, MD, MS

|  |  |
| --- | --- |
| **Current Position** | Associate Professor of MedicineClinical Director of Leukemia ServicesRobert H. Allen MD Endowed Chair in Hematology ResearchDivision of HematologyDepartment of MedicineUniversity of Colorado School of Medicine |

# Education and Postgraduate Training

|  |  |
| --- | --- |
| 1995 – 19991999 – 2003 2003 – 20062006 – 20072007 – 20102010 – 20112010 – 2011  | Indiana University, Bloomington, IN (Highest Distinction): BS, BiologyUniversity of Chicago Pritzker School of Medicine: MDUniversity of Chicago Hospitals: Internal Medicine Internship/Residency Cook County Hospital, Chicago, IL: Chief Medical ResidentStanford University: Fellow, Hematology/OncologyStanford University: Instructor, Hematology/OncologyStanford University: MS, Epidemiology |

**Academic Appointments**

|  |  |
| --- | --- |
| 2010-20112011 – 20162011 – Present2015 – Present2016 – Present | Stanford University: Instructor, Hematology/OncologyAssistant Professor, University of Colorado School of Medicine* Division of Hematology
* Blood Cancer and Bone Marrow Transplantation Program

Clinical Director of Leukemia ServicesMedical Director, Hematology Clinical Trials UnitAssociate Professor, University of Colorado School of Medicine |

**Professional Positions, Organizations and Committees**

Hospital

|  |  |
| --- | --- |
| 2011 – Present2011 – 20142012 – Present2012 – 201720132014 – 20162015 ­– 201920162016 – Present2019 – Present | University of Colorado Clinical Director of Leukemia ServicesUniversity of Colorado Cancer Center Scientific Review Committee (Protocol Review and Monitoring System)University of Colorado Hospital Pharmacy and Therapeutics Committee MemberHematology/Oncology Fellowship Selection CommitteeInternal Medicine Residency Candidate InterviewerUniversity of Colorado Cancer Center Data Safety Monitoring CommitteeMedical Director, Hematology Clinical Trials UnitUniversity of Colorado Department of Medicine Annual Research Day Planning CommitteeUniversity of Colorado Cancer Center Investigator Initiated Trials CommitteeClinical Trials Mentor, Hematology Clinical Trials Unit |

Non-Hospital (Regional and National)

|  |  |
| --- | --- |
| 2011 – Present2012 – Present2012 – 20172013 – Present2013 – Present20142014 – 20152015 – 20172018 – Present | Southwest Oncology Group, Leukemia Committee MemberLeukemia and Lymphoma Society Rocky Mountain Chapter Board of TrusteesAmerican Society of Hematology Committee on Government AffairsNational Comprehensive Cancer Network, Acute Myeloid Leukemia Committee MemberNational Comprehensive Cancer Network, Myelodysplastic Syndromes Committee MemberCancer League of Colorado, Scientific Advisory BoardLeukemia and Lymphoma Society of Canada, Scientific Advisory BoardNational Comprehensive Cancer Network, Myeloproliferative Neoplasms Committee Member (founding member)American Society of Hematology Working Group on Innovations in Clinical Trials |

**Honors, Special Recognitions and Awards**

|  |  |
| --- | --- |
| 1996 – 19991996 – 19991996199819991999 2001200220042004, 200520082008-2010200920102010201120132014 – Present201420152015 | Indiana University Founder’s Day Award (Dean’s list)Indiana University Biology Undergraduate Scholarship and Research GrantGolden Key National Honor SocietyPhi Beta KappaIndiana University Fox Glen Research and Education Fund Award for Outstanding Undergraduate Research Outstanding Senior Student, Department of Biology, Indiana UniversityAmerican Pediatric Society Medical Student Research AwardCalvin Fentress Senior Medical Student Research FellowAmerican Society of Hematology Annual Meeting Travel AwardUniversity of Chicago Department of Medicine Housestaff Scientific Session PresenterAmerican Society of Hematology Clinical Research Training Institute (CRTI) Participant, Dana Point, CAStanford Hematology/Oncology Annual Retreat Oral PresenterStanford Center for Clinical and Translational Education and Research (SCCTER) Intensive Course in Clinical ResearchWhite House Fellowship Regional FinalistStanford Clinical and Translational Research Networking ProgramAmerican Society of Clinical Oncology Annual Meeting Merit AwardAmerican Society of Hematology/European Hematology Association Translational Research Training in Hematology (TRTH) Workshop Participant, Milan, Italy Expert physician consultant, Grand Rounds virtual consultation serviceClinical Innovation Award, Division of HematologyGahanna Lincoln High School Hall of Fame InducteeUniversity of Colorado Department of Medicine Outstanding Early Career Scholar Awardee |
| 201520182018 | Conquer Cancer Foundation Scientific Career Development Retreat ParticipantLeukemia and Lymphoma Society Rocky Mountain Chapter “Chairman’s Quality of Life Award” Robert H. Allen MD Endowed Chair in Hematology Research |
|  |  |

**Licensure and Board Certification**

* Board certified in Internal Medicine 2006, recertification in 2016
* Board certified in Hematology 2010
* Board certified in Oncology 2011
* Colorado state medical license (2011) #DR-50375
* National Provider Number 1801915822
* State and Federal controlled substance licenses

**Review and Referee Work**

|  |  |
| --- | --- |
| 2011 | American Society of Hematology Annual Meeting Oral Session Moderator for Section: “Cytogenetics and Molecular Markers in Diagnosis and Prognosis: New Approaches to Personalized Therapy in Leukemia” |
| 2014 – 2016 | Leukemia and Lymphoma Society of Canada Annual Grant Reviewer |
| 2014 | American Society of Hematology Annual Meeting Oral Session Moderator for Section: “Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Molecular Targets and Drug Sensitivity in Myeloid Diseases” |
| 2014 | American Society of Hematology Annual Meeting Abstract Reviewer |
| 2014 | Cancer League of Colorado Grant Selection Committee |
| 2014 | American Society of Hematology Self-Assessment Program |
| 2014-2015 | American Society of Hematology Education Program |
| 2015-2017 | Data Safety Monitoring Board member, Glycomimetics Protocol GMI-1271-201, “A Phase I/II, Open-Label Multicenter Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia” |
| 2015 | National Comprehensive Cancer Network Young Investigator Award Grant Review Panelist for University of Colorado applicants |
| 2016 | American Society of Hematology Annual Meeting Oral Session Moderator for Section: “Acute Myeloid Leukemia: Clinical Studies: New Drugs for Older AML” |
| 2017 | United Kingdom Medical Research Council Clinical Scientist Fellowship Award reviewer |
| 2017 | American Society of Hematology Annual Meeting Abstract Reviewer |
| 2017 | American Society of Hematology Annual Meeting Oral Session Moderator for Section “Acute Myeloid Leukemia: Clinical Studies: Advances in Frontline Therapy: Induction, Consolidation, and Maintenance”  |
| 2017 – 2018 | Rising Tide Foundation for Clinical Cancer Research and Leukemia and Lymphoma Society Prevention Research Grant Review Committee |
| 2017 – Present | Independent Response Review Committee Chairman, Tolero Clinical Trial, TPI-ALV-201 |
| 2017 – Present | Leukemia and Lymphoma Society of Canada Blood Cancer Expert Reviewer Committee  |
| 201820182018 – Present | External reviewer for the University of Miami Miller School of Medicine promotion committeeLeuka Leukemia Research Foundation (UK) Grant Review CommitteeData Safety Monitoring Board Chairman for Glycomimetics Protocol No. GMI-1271-301, A Phase III, Randomized, Double-Blind Trial to Evaluate theEfficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia |
|  |  |

Reviewer at Large:

* Bone Marrow Transplantation
* Blood
* Annals of Internal Medicine (designated “Outstanding Reviewer” 2010)
* Annals of Oncology
* Journal of Clinical Oncology
* The Oncologist
* Haematologica
* Leukemia & Lymphoma
* Leukemia
* Public Library of Science (PLOS)
* OncoTargets and Therapy
* Pediatric Blood and Cancer
* Clinical Cancer Research
* Journal of the National Comprehensive Cancer Network
* International Journal of Hematology
* Blood Reviews
* Leukemia Research
* Journal of Visualized Experiments
* Biochemical Pharmacology
* Blood Advances
* Cancer
* HemaSphere

**Invited Lectures and Presentations**

Institutional

* Cancer Center Grand Rounds: August 30, 2011
* Developmental Therapeutics Retreat: September 8, 2011
* Department of Medicine’s Research and Innovation Series: November 17, 2011
* BMT Morbidity and Mortality Conference: February 28, 2012
* Phase 1 Team Lunch and Learn: June 21, 2012
* Department of Medicine Grand Rounds: March 13, 2013
* Multidisciplinary Leukemia Interest Group: February 7, 2014
* Obstetrics and Gynecology Grand Rounds, “Leukemia in Pregnancy”: April 9, 2014
* Bone marrow infusion center breakfast talk, “Clinical Trials in AML/MDS”: November 18, 2014
* Department of Medicine Faculty Conference Research in Motion, “Targeting Leukemia Stem Cells in Clinical Trials: New Rules, New Therapies, New Results”: February 26, 2015
* 1st Annual University of Colorado Hematologic Malignancies Retreat, “Targeting Leukemia Stem Cells in Clinical Trials: New Rules, New Therapies, New Results”: May 14, 2015
* 2nd Annual University of Colorado Hematologic Malignancies Retreat, “mRNA Splicing Genes and Infectious Risk in Myelodysplastic Syndromes”: May 2, 2016
* 2nd Annual Colorado Cancer Wellness Conference Panelist. September 17, 2016
* Research Advisory Forum, “Hematology Clinical Trials Unit”: October 19, 2016
* Department of Medicine Research and Innovation Conference, “Targeting Leukemia Stem Cells in Clinical Practice: Opportunities and Challenges” January 5, 2017
* University of Colorado Oncology Interest Group Lecture Series Panelist, April 17, 2017
* University of Colorado Pathology Department Grand Rounds, “New Therapies in AML” March 20, 2018
* University of Colorado Department of Medicine Grand Rounds, “Acute Myeloid Leukemia: From a Difficult Past to a Promising Future” August 29, 2018
* Schwartz Center Rounds, University of Colorado, panelist. “Celebrating Success!” December 14, 2018.

Regional

* Leukemia and Lymphoma Society Meet the Doctor Series: January 24, 2012, Denver CO
* Leukemia and Lymphoma Society Rocky Mountain Blood Cancer Conference: April 3, 2013, Denver CO
* Leukemia and Lymphoma Society: Journey of Hope Meeting: April 19, 2013, Denver CO
* Metro Denver Oncology Nursing Society’s Annual Conference: September 26, 2013, Denver CO
* Review of the 2014 American Society of Hematology Annual Meeting: February 6, 2015, Loveland CO
* “Low-intensity Therapeutic Advances in AML”: February 17, 2015, Billings MN via Webinar
* “Myeloproliferative Neoplasms: Contemporary Management and Unmet Needs”: June 8, 2015, Colorado Springs, CO
* “Myeloproliferative Neoplasms: Contemporary Management and Unmet Needs”: October 30, 2015, Poudre Valley Hospital, Ft. Collins, CO
* “Overview of Myeloid Malignancies.” November 14, 2015, University of Colorado, Aurora, CO. Oncology Boot Camp Conference.
* Review of the 2015 American Society of Hematology Annual Meeting: February 6, 2016, Colorado Springs, CO
* Leukemia and Lymphoma Society Rocky Mountain Blood Cancer Conference: April 16, 2016, Denver CO
* “Acute Myeloid Leukemia.” August 2, 2016, Celgene Medical Affairs Conference, Beaver Creek, CO
* “How Do We Treat MDS?” October 29, 2016, MDS Foundation Educational Patient and Family Forum, Aurora, CO
* “Key Developments and Evolving Strategies for Patients with Myeloproliferative Neoplasms.” October 24, 2016, Santa Fe, New Mexico
* Review of the 2016 American Society of Hematology Annual Meeting: January 27, 2017, Denver CO
* Leukemia and Lymphoma Society Rocky Mountain Blood Cancer Conference: April 8, 2017, Denver CO
* Acute Myeloid Leukemia MATTERS Summit, Faculty Panelist; May 3, 2017, Denver CO
* Myeloproliferative Neoplasms Panelist, Oncology Nursing Society meeting; May 5, 2017, Denver CO
* Leukemia and Lymphoma Society Rocky Mountain Blood Cancer Conference: April 7, 2018, Denver CO
* Targeted Oncology Case-Based Peer Perspectives Continuing Medical Education Talk. February 26, 2019, Denver CO

National

* “Acute Myeloid Leukemia: Past, Present and Future.” Ohio State University East Grand Rounds, Columbus, OH. September 18, 2009
* “The Utility of Influenza Vaccination for Oncology Patients.” City of Hope Cancer Center, Duarte, CA. October 16, 2012
* Highlights of the Annual American Society of Hematology Meeting: Myelodysplastic Syndrome. Dallas, TX January 17, 2014.
* Highlights of the Annual American Society of Hematology Meeting: Myelodysplastic Syndrome. San Francisco, CA January 24, 2014.
* “Low-Intensity Therapeutic Advances in AML.” Virginia G. Piper Cancer Center Grand Rounds, Scottsdale AZ. October 28, 2014
* “Low-Intensity Therapeutic Advances in AML.” University of Pittsburgh Hillman Cancer Center Grand Rounds, Pittsburgh, PA. February 16, 2015
* “Low-Intensity Therapeutic Advances in AML.” Rush University Grand Rounds, Chicago, IL. March 25, 2015
* “Low-Intensity Therapeutic Advances in AML.” Olive View-UCLA Medical Center Grand Rounds. March 31, 2015.
* “New Therapeutic Advances in Acute Myeloid Leukemia.” Cancer Treatment Centers of America, Annual New Treatments in Oncology Conference (ANTO), Scottsdale, AZ. May 2, 2015.
* “Myeloproliferative Neoplasms: Contemporary Management and Unmet Needs.” Ohio State University East, Columbus, OH. May 7, 2015.
* “Acute Myeloid Leukemia: Applying Emerging Evidence in Practice.” First Annual Twin Cities Hematologic Malignancies Symposium, Minneapolis, MN. October 24, 2015.
* “Targeting Leukemia Stem Cells and Therapeutic Interventions in AML Subpopulations.” BEAT AML Forum, Portland OR. October 27, 2015.
* “Emerging Agents in Myeloid Malignancies.” American Society of Clinical Oncology Oral Abstract Session Discussant, Chicago IL. June 4, 2016.
* “Targeted Therapies for Acute Myeloid Leukemia.” Celgene AML and MDS Workshop, Newark NJ. September 23, 2016.
* “Targeting Leukemia Stem Cells in Clinical Practice: Opportunities and Challenges.” BEAT AML Symposium, Portland OR. October 14, 2016.
* “Assessing Potential Therapeutic Targets in AML.” Highlights of the American Society of Hematology Meeting Satellite Session, Atlanta, GA. January 13, 2017.
* Highlights of the 2016 American Society of Hematology Meeting. Celgene Headquarters, Summit, NJ. February 10, 2017.
* “Acute Myeloid Leukemia Treatment Options.” Webinar, sponsored by Leukemia and Lymphoma Society and the National Marrow Donor Program. May 16, 2017.
* “Venetoclax and Azacitidine in AML: Clinical Experience and Preliminary Correlative Studies.” BEAT AML Forum, Portland, OR. September 12, 2017.
* “BCL-2 Inhibition in AML.” Society of Hematologic Oncology. Houston, TX September 14, 2017.
* “Targeting BCL-2: Venetoclax Combinations and Increasing Off-Label Use.” 4th Annual Think Tank on Integrating New Molecular Targets in acute Leukemias and Myeloproliferative Neoplasms. Dallas, TX January 26-27, 2018.
* “Updates on Myelodysplastic Syndromes.” 2018 Lymphoma Study Group/Hematology Highlights: A Post ASH Review Conference. Ohama, NE February 2-3, 2018.
* “The Herculean Task of Targeting AML Stem Cells.” Emil J. Freireich Leukemia Hematology Grand Rounds, MD Anderson. Houston, TX, February 21, 2018.
* “The Herculean Task of Targeting AML Stem Cells.” The University of Miami March 12, 2018.
* “The Herculean Task of Targeting AML Stem Cells.” Stanford University, March 27, 2018.
* “Which Novel Agents in AML are Likely to Change Practice?” Acute Leukemia Conference, April 13, 2018, Newport Beach, CA.
* Venetoclax in AML: Background Data and Possible Indications. NCCN AML Committee Meeting, May 15, 2018, Philadelphia, PA.
* University of Utah Division of Hematology Symposium and retreat, invited guest speaker. “The Herculean Task of Targeting Leukemia Stem Cells.” Deer Valley Utah, June 8-9 2018
* Leukemia and Lymphoma Society National Board of Directors Meeting Medical and Scientific Affairs Committee Meeting. Special Session on AML. “Targeting AML Stem Cells Through Inhibition of BCL-2: The Current Landscape and Future Directions. Rye Brook NY, June 29, 2018.
* National Comprehensive Cancer Network Congress Series on Acute Leukemia. “Advances in AML Management in Older Patients. Columbus, OH, August 15, 2018.
* American Society of Hematology Educational Session. Acute Myeloid Leukemia: Moving Beyond 7+3. Invited Lecture: New Drugs Inspired by Genomics and When to Use Them. December 1, 2018, San Diego.
* “The Herculean Task of Targeting AML Stem Cells.” The University of Texas Southwestern. February 5, 2019, Dallas.
* “The Herculean Task of Targeting AML Stem Cells.” Research Affinity Group lecture series, Children’s Hospital of Phladelphia Research Institute, University of Pennsylvania. February 25, 2019, Philadelphia.

International

* **“Clinical Predictors of Transplant Related Mortality After Reduced Intensity Allogeneic Stem Cell Transplantation”. *European Hematology Association 10th Congress*, June 2-5, 2005. Stockholm, Sweden (poster presentation)**
* **“**A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.” *Targeted Anticancer Therapy Conference*, March 4-6, 2013. Paris, France (poster presentation)
* “Clinical Safety and Activity in a Phase I Trial of AG-120, a First in Class, Selective, Potent Inhibitor of the IDH1-Mutant protein, in Patients with IDH1 Mutant Positive Advanced Hematologic Malignancies.” *EORTC-NCI-AACR Symposium*, November 18-21, 2014. Barcelona, Spain (oral presentation)
* “Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study.” European Hematology Association, June 17 2018. Stockholm, Sweden (oral presentation)
* “Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant IDH2 Acute Myeloid Leukemia.” European Hematology Association, June 17, 2018. Stockholm, Sweden (oral presentation)
* “BCL-2 Inhibition to Target AML Stem Cells.” 10th International Heinrich F.C. Behr Symposium on Stem Cells and Cancer, Workshop on Innovative Strategies to Target AML. September 16, 2018. Heidelberg, Germany.
* “Targeting BCL-2 in CLL and AML.” Japanese Society of Hematology 80th Annual Meeting. October 12, 2018. Osaka, Japan.
* “The Herculean Task of Targeting AML Stem Cells.” Japanese Society of Hematology Luncheon Seminar. October 14, 2018. Osaka, Japan.
* “Treatment of AML Without a FLT3 or IDH Mutation.” Spanish Hematology and Hemotherapy Society Global AML Educations Scientific Forum. March 30, 2019. Barcelona, Spain.
* “The Herculean Task of Targeting AML Stem Cells.” University of Toronto Princess Margaret Hospital, Leukemia Academic Grand Rounds. April 1, 2019, Toronto, Canada.

**Media Appearances and Interviews**

ABC7 News (Denver ABC affiliate). February 6, 2019.

[Man in remission has hope for life after cancer treatment trial](https://www.thedenverchannel.com/franchise/indian-river-lagoon/health/man-in-remission-has-hope-for-life-after-cancer-treatment-trial)

CBS4 News (Denver CBS affiliate). March 11, 2019.

<https://denver.cbslocal.com/2019/03/11/new-treatment-at-colorado-cancer-center-is-possible-cure-for-aml/>

CBS4 News (Denver CBS affiliate). April 7, 2019. <https://denver.cbslocal.com/video/4061477-cancer-patient-celebrated-at-rockies-game/>

Colorado Matters on Colorado Public Radio. April 5, 2019.

<https://www.cpr.org/news/story/this-cu-drug-trial-may-cure-an-aggressive-strain-of-leukemia-including-this-canon-city>

9News (Denver NBC affiliate). April 8, 2019. <https://www.9news.com/article/news/local/next/new-drug-trial-at-cu-anschutz-may-be-a-cure-to-a-strain-of-leukemia/73-f85b0afe-5b7c-448c-909f-98a547b69d03>

**Teaching Record**

* Medical Residency Lecture Series: Leukemia May 29, 2012
* Cancer Research Summer Fellowship lecture, “Acute Myeloid Leukemia: An Overview and Hopeful Future Directions”: July 16, 2015, June 21, 2016, July 18, 2017, July 17, 2018
* Internal Medicine Residency Program Wednesday Education Sessions “Myeloid Malignancies, Parts 1 and 2”: November 11, 2015 and March 16, 2016
* IDPT 7656: Advanced Foundations of Doctoring**,** 2015- Current
	+ Course for MSTP students to maintain and further clinical skills learned during training
* IMMU 7603: The Immunologic Basis of Human Disease, 2016, 2017
	+ Course for immunology program graduate students to provide a mechanistic and clinical understanding of the immunologic basis of human disease
* Internal Medicine Residency panel discussion on academic careers in medicine, October 2, 2018
* BMT Grand Rounds (multiple annual presentations 2011 to present, including AML, CLL, CML, MDS, ALL, MPNs)
* Hematology/Oncology Fellows Conferences (multiple annual presentations from 2011 to present, including AML, ALL, MDS)

**Self-Improvement**

* Junior Faculty Mentor Program (JUMP) Workshop, University of Colorado Department of Medicine; focus on developing mentorship skills, Winter/Spring 2016
* Clinical Leadership Development Program, University of Colorado, November/December 2016
* University of Colorado Leadership for Innovative Team Science (LITeS) Program, 2017-2018
* A Competency-Based Approach to Principal Investigator Responsibilities Workshop, University of Colorado, November 6, 2018

Ward and Clinic Attending Duties

2011 – Present: Supervision and bedside teaching of medical students, residents, fellows, nurse practitioners and physicians’ assistants, 3-4 months/year inpatient (~25 inpatients/day), two half-days a week outpatient (~20 patients/week)

Other Administrative Duties

2015 – Present: Co-course director (with Jeffrey Schowinsky), myeloid malignancies didactic series for internal medicine residents

2013 – Present: Director of the Leukemia and Myelodysplastic Syndromes Quality Improvement Committees, responsible for publishing internal practice management guidelines for leukemia at the University of Colorado

Mentees

Zohra Nooruddin

2014-2016

Hematology/oncology fellow

Now faculty at San Antonio VA Hospital

Henning Schade

2014-2016

Hematology/oncology fellow

Now in private practice

Biniam Adane

2013-Current

Graduate student, Jordan laboratory

Mentorship committee member

Awarded PhD in 2018

Now a post-doctoral fellow

Katherine Minson

2014

Pediatric hematology/oncology fellow

Laboratory of Doug Graham

Scholarship oversight committee member

Now on faculty at Emory University

Kelly Higa

2015-Current

MD/PhD candidate, DeGregori laboratory

Associate mentor, T32 Training Grant

Anagha Inguva

2016-Current

MD/PhD candidate

Clinical preceptor

Enkhtsetseg Purev, MD, PhD

2015-Current

Junior Faculty in the Hematology Division

Bradley Haverkos, MD

2015-Current

Junior Faculty in the Hematology Division

Peter Forsberg, MD

2016-Current

Junior Faculty in the Hematology Division

Courtney Jones, PhD

2016-Current

Postdoctoral Fellow

Career Development Committee

James Dugan, MD

2016-Current

Hematology/Oncology fellow

Hae J Park

2018-Current

MD/PhD candidate

Thesis committee member

**Grant Support**

Active

PI: Daniel A. Pollyea

Title: A clinical and translational developmental therapeutics program focused

on targeting leukemia stem cells

Agency: University of Colorado Department of Medicine Outstanding Early Career Scholars Program

Period: 7/1/15-6/30/20

Award: $375,000 (total direct costs)

PI: Daniel A. Pollyea

Title: Targeting Leukemia Stem Cells in the Clinical Setting: The Development of a Comprehensive Program

Agency: Leukemia and Lymphoma Society Scholar in Clinical Research

Period: 7/1/19-6/30/24

Award: $625,000 (total direct costs)

Completed

PI: Daniel A. Pollyea

Title: Targeting the hedgehog signaling pathway in post allogeneic stem cell transplant patients

Agency: Leukemia and Lymphoma Society Therapy Acceleration Program

Period: 7/1/13-6/30/16

Award: $354,000 (total direct costs)

Co-PI: Daniel A. Pollyea

Title: Characterization and targeting of MDS stem cells

Agency: Edward P. Evans Foundation, MDS Basic Science Research Grant

Period: 7/1/15-6/30/17

Award: $400,000 (total direct costs)

Co-I: Daniel A. Pollyea

Title: Targeting unique metabolic dependencies to eradicate leukemia stem cells Agency: Leukemia and Lymphoma Society Therapy Acceleration Program

Agency: University of Colorado Department of Medicine Team Science Award

Period: 2016

Award: $40,000

PI: Daniel A. Pollyea

Title: Targeting cancer stem cells through inhibition of Bcl-2 in acute myeloid leukemia and myelodysplastic syndrome

Agency: NIH Loan Repayment Program

Period: 7/1/10-6/30/17

Agency: NIH KL2 Mentored Career Development Award

Period: 7/1/09-6/30/11

PI: Daniel A. Pollyea

Agency: American Society of Clinical Oncology Young Investigator Award

Period: 7/1/09-6/30/10

Award: $50,000

PI: Daniel A. Pollyea

Agency: American Society of Hematology Research Training Award for Fellows

Period: 7/1/09-6/30/10

Award: $50,000

PI: Daniel A. Pollyea

Agency: Leukemia and Lymphoma Society Special Fellow in Clinical Research Career Development Award

Period: 7/1/10-6/30/13

Award: $195,000

PI: Daniel A. Pollyea

Agency: Cancer League of Colorado Pilot Grant: Ibrutinib with lenalidomide for chronic lymphocytic leukemia

Period: 7/1/13-6/30/15

Award: $30,000

PI: Daniel A. Pollyea

Title: Lenalidomide in leukemia clinical trials

Agency: American Society of Clinical Oncology Career Development Award

Period: 7/1/13-6/30/16

Award: $200,000

Co-PI: Daniel A. Pollyea

Title: mRNA splicing, innate immunity and the pathogenesis of MDS

Agency: Cancer League of Colorado Pilot Grant

Period: 7/1/15-6/30/16

Award: $30,000

Co-PI: Daniel A. Pollyea

Title: Splicing gene mutations and infection in MDS patients

Agency: Cancer League of Colorado Pilot Grant

Period: 7/1/16-6/30/17

Award: $30,000

Not Funded

|  |  |  |  |
| --- | --- | --- | --- |
| Co-PI | Targeting cancer stem cells through inhibition of Bcl-2 in acute myeloid leukemia | R01CA197524 |  |
| PI | Novel therapeutic combinations with lenalidomide for relapsed and refractory leukemia | K23CA177873 |  |
| Co-PI | mRNA splicing and the pathogenesis of hematological malignancies | R21 NCI CA195160 | Impact score 25, 10th percentile (7-17-15) |
| Co-PI | Characterization of MDS stem cells and development of novel therapeutics | R21 NCI CA198445 | Impact score 25, 10th percentile (12-9-15) |

**Bibliography**

Peer-Reviewed Manuscripts

1. Huang J, Frischer JS, New T, Kim EG, Serur A, Lee A, Kadenhe-Chiwishe A, **Pollyea DA**, Yokoi A, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ. TNP-470 promotes initial vascular sprouting in xenograft tumors. *Molecular Cancer Therapeutics*, 2004;3(3):335-343. [PMID: 15026554](http://mct.aacrjournals.org/content/3/3/335)
2. Kline J, **Pollyea DA**, Stock W, Artz A, Rich E, Godley L, Zimmerman T, Thompson K, Pursell K, Larson RA, van Besien K. Pre-transplant Ganciclovir and post-transplant high-dose valacyclovir reduce CMV infections after alemtuzumab based conditioning. *Bone Marrow Transplant* 2006;3:307-10. [PMID: 16400339](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:16400339)
3. Artz A, **Pollyea D**, Kocherginsky M, Daugherty C, Zimmerman T, Smith S, Godley L, Thirman M, Rich E, Larson R, Stock W, Balducci L, Van Besien K. Performance status and comorbidity determine transplant related mortality after allogeneic hematopoietic cell transplantation. *Biology of Blood and Marrow Transplant.* 2006 Sep;12(9):954-64. [PMID: 16920562](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:16920562)
4. Michaelis L, Lin S, Joseph L, Artz AS, Kline J, **Pollyea D**, Stock W, Rich E, Collins-Jones D, Casey B, Cerro PD, van Besien K. Chimerism does not predict for outcome after alemtuzumab based conditioning. *Bone Marrow Transplant*. 2007 Jul;40(2):181. [PMID: 17502895](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:17502895)
5. **Pollyea DA**, Artz A, Stock W, Daugherty C, Godley L, Odenike O, Rich E, Smith S, Zimmerman T, Zhang Y, Huo D, Larson R, Van Besien K. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant.* 2007 Dec;40(11):1027-32. [PMID: 17846595](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:17846595)
6. **Pollyea DA**, George TI, Corless C, Gotlib J. When yellow jackets attack: Recurrent and severe anaphylactic reactions to insect bites and stings. *American Journal of Hematology*. 2009 Dec;84(12):843-6. [PMID: 19862831](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:19862831)
7. **Pollyea DA,** Brown J, Horning SJ. The utility of influenza vaccination for oncology patients. *Journal of Clinical Oncology*. 2010 May 10;28(14):2481-90. [PMID: 20385981](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:20385981)
8. Kohrt H, Patel P, Ho M, Owen T, **Pollyea D**, Majeti R, Gotlib J, Coutre S, Liedtke M, Berube C, Alizadeh A, and Medeiros B. Second line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. *American Journal of Hematology.* 2010 Nov;85(11):877-81. [PMID: 20872554](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:20872554)
9. Huang M, Whang P, Chodaparambil JV, **Pollyea DA**, Kusler B, Xu L, Felsher DW, Mitchell BS. Reactive oxygen species regulate nucleostemin oligomerization and protein degradation. *Journal of Biological Chemistry*. 2011 Apr 1;286(13):11035-46. [PMID: 21242306](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:21242306)
10. **Pollyea DA,** Kohrt HE, Medeiros BC. Acute Myeloid Leukemia in the Elderly: A Review. *British Journal of Haematology.* 2011 Mar; 152(5):524-42. [PMID: 21314823](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:21314823)
11. **Pollyea DA,** Raval A, Kusler B, Gotlib JR, Alizadeh AA, Mitchell BS. [Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors.](http://www.ncbi.nlm.nih.gov.laneproxy.stanford.edu/pubmed/21922510) *Hematological Oncology.* 2011 Sep;29(3):157-60. [PMID: 21922510](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:21922510)
12. **Pollyea DA,** Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B, Bhattacharya S, Zehnder J, Liedtke M, Gotlib JR, Coutre S, Berube C, Melnick A, Levine R, Mitchell BS, Medeiros BC. Safety, Efficacy and Biological Predictors of Response to Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia. *Leukemia.* 2012 May;26(5):893-901. [PMID: 22033493](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:22033493)
13. **Pollyea** **DA**, Kohrt HE, Zhang B, Zehnder J, Schenkein D, Fantin V, Straley K, Vasanthakumar A, Abdel-Wahab O, Levine R, Godley LA, Medeiros BC. [2-Hydroxyglutarate in IDH Mutant AML: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels.](http://www.ncbi.nlm.nih.gov.laneproxy.stanford.edu/pubmed/22680765) *Leuk Lymphoma.* 2013 Feb;54(2):408-10. [PMID: 22680765](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:22680765)
14. **Pollyea DA**, Zehnder J, Coutre S, Gotlib J, Gallegos L, Abdel-Wahab O, Greenberg P, Zhang B, Liedtke M, Berube C, Levine R, Mitchell BS, Medeiros BC. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. *Haematologica.* 2013 Apr;98(4):591-6. [PMID: 23252596](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:23252596)
15. Coffey DG, **Pollyea DA**, Myint H, Smith C, Gutman JA. Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index. Bone Marrow Transplant. 2013 Sep;48(9):1253-6. [PMID:23503530](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:23503530)
16. Narayanan V, **Pollyea DA**, Gutman JA, Jimeno A. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. *Drugs Today* (Barc). 2013 Apr;49(4):261-9. [PMID: 23616953](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:23616953)
17. Maxson JE, Gotlib J, **Pollyea DA**, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW. [Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.](http://www.ncbi.nlm.nih.gov/pubmed/23656643) *New England Journal of Medicine*. 2013 May 9;368(19):1781-90. [PMID: 23656643](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:23656643)
18. Narayanan V, Gutman JA, **Pollyea** DA, Jimeno A. [Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.](http://www.ncbi.nlm.nih.gov/pubmed/23914353) *Drugs Today*. 2013 Jul;49(7):447-56. [PMID: 23914353](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:23914353)
19. Ravandi F, Erba HP, **Pollyea DA**. Expert insights into the comtemporary management of older adults with acute myeloid leukemia. *Cancer Control.* 2013 Oct;20(4 Suppl):5-16. [PMID: 24077448](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:24077448)
20. Smith C, Gasparetto M, Humphries K, **Pollyea** DA, Vasiliou V, Jordan CT. Aldehyde dehydrogenases in acute myeloid leukemia. *Ann N Y Acad Sci.* 2014 Mar;1310(1):58-68. [PMID: 24641679](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:24641679)
21. Gardner LA, Klawitter J, Gregory MA, Zaberezhnyy V, Baturin D, **Pollyea DA**, Takebe N, Christians U, Gore L, DeGregori J, Porter CC. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1+ leukemia. American Journal of Hematology. 2014 Sep;89(9):896-903. [PMID:24891015](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:24891015)
22. **Pollyea DA**, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. *Haematologica*. 2014 Aug;99(8):1277-1284. [PMID:25082785](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:25082785)
23. Pollyea DA, Gutman JA. Stopping Higher-Risk Myelodysplastic Syndrome in Its Tracks. *Curr Hematol Malig Rep*. 2014 Dec;9(4):421-31.[PMID:25208927](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:25208927)
24. Smith C, Gasparetto M, Jordan C, Pollyea DA, Vasiliou V. The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. *Adv Exp Med Biol*. 2015;815:349-59. [PMID:25427917](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:25427917)
25. Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, Jordan CT, Serkova NJ, Graham DK, DeGregori J. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clinical Cancer Research. 2015 Mar 15;21(6):1360-72. [PMID: 25547679](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:25547679)
26. Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C.Myelodysplastic syndromes, version 2.2015. *Journal of the National Comprehensive Cancer Network*. 2015 Mar;13(3):261-72. [PMID: 25736003](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:25736003)
27. Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. *Journal of the National Comprehensive Cancer Network*. 2015 Apr;13(4):424-34. [PMID: 25870379](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:25870379)
28. Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N, Singh J, Padgett RA, Gu X, Phillips JG, Clemente M, Parker Y, Lindner D, Dienes B, Jankowsky E, Saunthararajah Y, Du Y, Oakley K, Nguyen N, Mukherjee S, Pabst C, Godley LA, Churpek JE, Pollyea DA, Krug U, Berdel WE, Klein HU, Dugas M, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Yoshida K, Ogawa S, Müller-Tidow C, Maciejewski JP. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell. 2015 May 11;27(5):658-70. [PMID: 25920683](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:25920683)
29. Koo GB, Morgan MJ, Lee DG, Kim WJ, Yoon JH, Koo JS, Kim SI, Kim SJ, Son MK, Hong SS, Levy JM, Pollyea DA, Jordan CT, Yan P, Frankhouser D, Nicolet D, Maharry K, Marcucci G, Choi KS, Cho H, Thorburn A, Kim YS. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Research. 2015 Jun;25(6):707-25. [PMID: 25952668](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:25952668)
30. Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, Jordan CT, Lee C, Swisshelm K, Tobin J, Wei Q, Schowinsky J, RInella S, Lee H, Pollyea DA. Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series. *Leukemia and Lymphoma*. 2016 Apr;57(4):927-34. [PMID: 26389776](http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:26389776)
31. Smith KS, Yadav VK, Pei S, Pollyea DA, Jordan CT, De S. SomVarIUS: Somatic variant identification from unpaired tissue samples. *Bioinformatics*. 2016 Mar 15;32(6):808-13. PMID:26589277
32. Lewinsohn M, Brown AL, Weinel LM, Phung C, Rafidi G, Lee MK, Schreiber AW, Feng J, Babic M, Chong CE, Lee Y, Yong A, Suthers GK, Poplawski N, Altree M, Phillips K, Jaensch L, Fine M, D'Andrea RJ, Lewis ID, Medeiros BC, Pollyea DA, King MC, Walsh T, Keel S, Shimamura A, Godley LA, Hahn CN, Churpek JN, Scott HS. Novel germline DDX41 mutations define families with a lower age of MDS/AML onset, and lymphoid malignancies. *Blood*. 2016 Feb 25;127(8):1017-23. PMID:26712909
33. Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T, Bernt KM. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. *J Clin Invest*. 2016 Apr 1;126(4):1438-50. PMID: 26927674
34. Gutman JA, Ross K, Smith C, Myint H, Lee CK, Salit R, Milano F, Delaney C, Gao D, Pollyea DA. Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation. *Bone Marrow Transplant*. 2016 Jul11. Epub ahead of print. PMID: 27400068
35. Konopleva M, **Pollyea DA**, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. *Cancer Discov*. 2016 Aug 12. Epub ahead of print. PMID: 27520294
36. Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, **Pollyea DA**, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. *BMC Cancer*. 2016 Aug 19;16:652. E pub ahead of print. PMID: 27538433
37. Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, **Pollyea** **DA**, Crooks PA, Smith C, Jordan CT. Rational Design of a Parthenolide-based Drug Regimen that Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. *J Biol Chem*. 2016 Aug 29. Epub ahead of print. PMID: 27573247
38. Medeiros BC, Fathi AT, DiNardo CD, **Pollyea** **DA**, Chan SM, Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies. *Leukemia*. 2016 Oct 10. PMID:27721426
39. Gregory MA, D'Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Adane B, Rozhok AI, Kumar A, Kumar V, **Pollyea** **DA**, Wempe MF, Jordan CT, Serkova NJ, Tan AC, Hansen KC, DeGregori J. ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. *Proc Natl Acad Sci U S A*. 2016 Oct 25;113(43):E6669-E6678. PMID: 27791036
40. Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, **Pollyea DA**, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2016 Dec;14(12):1572-1611. PMID:27956542
41. Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, **Pollyea** **DA**, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2017 Jan;15(1):60-87. PMID:28040720
42. **Pollyea DA**, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. *Blood*. 2017 Feb 3. doi: 10.1182/blood-2016-10-696039. [Epub ahead of print] PMID:28159738
43. Nooruddin Z, Miltgen N, Wei Q, Schowinsky J, Pan Z, Tobin J, Purev E, Gutman JA, Robinson W, **Pollyea** DA. Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. *Haematologica*. 2017 Feb 16. doi: 10.3324/haematol.2016.163089. [Epub ahead of print] PMID: 28209656
44. Gasparetto M, Pei S, Minhajuddin M, Khan N, **Pollyea** **DA**, Myers JR, Ashton JM, Becker MW, Vasiliou V, Humphries KR, Jordan CT, Smith CA. Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1. *Haematologica*. 2017 Mar 9. [Epub ahead of print] PMID: 28280079
45. Carey A, Edwards DK 5th, Eide CA, Newell L, Traer E, Medeiros BC, **Pollyea** **DA**, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A. Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. *Cell Rep*. 2017 Mar 28;18(13):3204-3218. PMID:28355571
46. Stein EM, DiNardo CD, **Pollyea DA**, Fathi AT, Roboz GJ, Altman JK, Stone RM,DeAngelo DJ, Levine RL, Flinn WI, Kantarjian H, Collins R, Patel MR, Franel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Enasidenib inmutant-IDH2 relapsed or refractory acute myeloid leukemia. *Blood*. 2017 Jun 6. Epub ahead of print. PMID: 28588020.
47. Melani C, Major A, Schowinsky J, Roschewski M, Pittaluga S, Jaffe ES, Pack SD, Abdullaev Z, Ahlman MA, Kwak JJ, Morgan R, Rabinovitch R, Pan Z, Haverkos BM, Gutman JA, **Pollyea** **DA**, Smith CA, Wilson WH, Kamdar M. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. *New England Journal of Medicine*. 2017 Jul 6;377(1):89-91. doi: 10.1056/NEJMc1704767. PMID:28679093
48. O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Gore SD, Hall AC, Kropf P, Lancet J, Maness LJ, Marcucci G, Martin MG, Moore JO, Olin R, Peker D, **Pollyea** **DA**, Pratz K, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wang ES, Wieduwilt M, Gregory K, Ogba N. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2017 Jul;15(7):926-957. doi: 10.6004/jnccn.2017.0116. PMID:28687581
49. Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, Enlight I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, **Pollyea DA,** Medeiros BC, Traer E, Tognon CE, Mori M, Druker BJ, Tyner JW. Molecularly Targeted Drug Combinations Demonstrate Selective Effectiveness for Myeloid- and Lymphoid-Derived Hematologic Malignancies. *Proc Natl Acad Sci USA*. 2017 Aug 7. doi: 10.1073/pnas.1703094114. PMID: 1703094114 [Epub ahead of print]
50. Stansfield LC, **Pollyea DA.** Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia. *Pharmacotherapy*. 2017 Oct 4. doi: 10.1002/phar.2039. [Epub ahead of print] PMID: 28976600
51. Medeiros BC, McCaul K, Kambhampati S, **Pollyea DA**, Kumar R, Silverman LR, Kew A, Saini L, Beach CL, Vij R, Wang X, Zhong J, Gale RP. Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide or azacitidine in persons ≥65 years with newly-diagnosed acute myeloid leukemia. *Haematologica*. 2017 Nov 2. pii: haematol.2017.172353. doi: 10.3324/haematol.2017.172353. [Epub ahead of print] PMID: 29097499
52. DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, **Pollyea DA**. Safety and preliminary efficacy of venetoclax with decitaibne or azacitidine in elderly patients with previously untreated acyte myeloid leukemia: a non-randomized, open label, phase 1b study. *Lancet Oncology*. 2018 Feb;19(2):216-228. Epubl 2018 Jan 12. PMID: 29339097.
53. Savona MR, **Pollyea DA**, Stock, W, Oehler VG, Schroeder MA, Lancet JE, McCloseky J, Kantarjian HM, Ma WW, Shaik MN, Larid AD, Zeremski M, O’Connell A, Chan G, Cortes JE. Phase 1b study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS. *Clin Cancer Res*. 2018 Feb 20. Epub ahead of print. PMID: 29463550
54. **Pollyea DA**, Hedin BR, O'Connor BP, Alper S. Monocyte function in patients with myelodysplastic syndrome. *J Leukoc Biol*. 2018 Apr 14. doi:10.1002/JLB.5AB1017-419RR. Epub ahead of print. PMID: 29656609
55. Sharma P, **Pollyea DA**, Smith CA, Purev E, Kamdar M, Haverkos B, Sherbenou D, Rabinovitch R, Hammes A, Gutman JA. Thiotepa based intensified reduced intensity conditioning adult double-unit cord blood hematopoietic stem cell transplantation results in deceased relapsed rate and improved survival compared to transplantation following standard reduced intensity conditioning: a retrospective cohort comparison. *Biol Blood Marrow Transplant*. 018 Apr 20. pii: S1083-8791(18)30200-3. doi: 10.1016/j.bbmt.2018.04.019. [Epub ahead of print] PMID:29684565
56. Amaya ML, **Pollyea DA**. Targeting the IDH2 Pathway in Acute Myeloid Leukemia. *Clin Cancer Res*. 2018 May 16. pii: clincanres.0536.2018. doi: 10.1158/1078-0432.CCR-18-0536. [Epub ahead of print] PMID:29769206
57. Dugan J, **Pollyea DA**. Enasidenib for the treatment of acute myeloid leukemia. *Expert Rev Clin Pharmacol*. 2018 May 17. doi:10.1080/17512433.2018.1477585. [Epub ahead of print] PMID:29770715
58. DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, **Pollyea DA**, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. *New England Journal of Medicine*. 2018 Jun 2. doi: 10.1056/NEJMoa1716984. [Epub ahead of print] PMID: 29860938
59. Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, **Pollyea DA**, Smith CA, Jordan CT. AMPK/FIS1-Mediated Mitophagy is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell. 2018 Jun 6. pii: S1934-5909(18)30239-X. doi: 10.1016/j.stem.2018.05.021. [Epub ahead of print] PMID: 29910151
60. Sharma P, **Pollyea DA**. Shutting Down Acugte Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition. Curr Hematol Malig Rep. 2018 Jul 7. doi: 10.1007/s11899-018-0464-8. [Epub ahead of print] PMID:29982865
61. **Pollyea DA**. Next-Generation Sequencing and Eating of the Tree of Knowledge. Clin Cancer Res. 2018 Jul 23. pii: clincanres.1835.2018. doi: 10.1158/1078-0432.CCR-18-1835. [Epub ahead of print] PMID:30037820
62. Cortes JE, Smith BD, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, **Pollyea DA**, Sekeres MA, Robak T, Ma WW, Zeremski M, Shaik MN, Laird AD, O'Connell A, Chan G, Schroeder MA. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol. 2018 Aug 3. doi: 10.1002/ajh.25238. [Epub ahead of print] PMID:30074259
63. Stevens BM, Khan N, D’Alessandro A, Nemkov T, Winters A, Jones CL, Zhang W, **Pollyea DA**, Jordan CT. Characterization and targeting of malignant stem cells in patients with advanced myelodsysplastic syndromes. Nat Commun. 2018 Sept 12;9(1):3694. PMID: 30209285.
64. Ye H, Adane B, Khan N, Alexeev E, Nusbacher N, Minhajuddin M, Stevens BM, Winters AC, Lin X, Ashton JM, Purev E, Xing L, **Pollyea DA**, Lozupone CA, Serkova NJ, Colgan SP, Jordan CT. Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. *Cancer Cell*. 2018 Oct 8;34(4):659-673. PMID: 30270124.
65. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, **Pollyea** **DA**, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ. Functional genomic landscape of acute myeloid leukaemia. *Nature*. 2018 Oct;562(7728):526-531. PMID:30333627.
66. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Franfurt O, Konopleva M, We AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, **Pollyea DA**, Letai A. Venetodlax combined with decitabine or azactidine in treatment-naïve, elerdly patients with acute myeloid leukemia. *Blood*. 2018 Oct 25, Epub ahead of print, PMID: 30361262.
67. **Pollyea DA**, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D’Alessandro A, Culp-Hill R, Riemondy KA. Gillen AE, Hesselbert JR, Abbott D, Schatz D, Gutman JA, Purev E, Smith C, Jordan CT. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in acute myeloid leukemia patients. *Nat Med*. 2018 Nov 12. doi: 10.1038/s41591-018-0233-1. [Epub ahead of print] PMID: 30420752
68. Jones CL, Stevens BM, D’Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Reinhold D, Smith C, DeGregori J, **Pollyea DA**, Jordan CT. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. *Cancer Cell*. 2018 Nov 12;34(5):724-740.e4. doi: 10.1016/j.ccell.2018.10.005. PMID:30423294
69. **Pollyea DA**. Which novel agents for acute myeloid leukemia are likely to change practice? *Best Pract Res Clin Haematol*. 2018 Dec;31(4):391-395. Epub 2018 Sep 20. Review. PMID:30466754
70. Stein EM, DiNardo CD, Fathi AT, **Pollyea** DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S. Molecular remission and response patterns in patients with mutant-*IDH2* acute myeloid leukemia treated with enasidenib. *Blood*. 2018 Dec 3. [Epub ahead of print] PMID: 30510081
71. **Pollyea DA**. New drugs for acute myeloid leukemia inspired by genomics and when to use them. *Hematology Am Soc Hematol Educ Program*. 2018 Nov 30;2018(1):45-50. PMID: 30504290
72. Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, **Pollyea** DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. *Leukemia*. 2018 Dec 16. [Epub ahead of print] PMID: 30555165
73. **Pollyea DA**, Jordan CT. Why are hypomethyating agents or low-dose cytarabine and venetoclax so effective? *Curr Opin Hematol*. 2019 Mar;26(2):71-76. PMID:30652974
74. **Pollyea DA**, Harris C, Rabe JL, Hedin BR, De Arras L, Katz S, Wheeler E, Bejar R, Walter MJ, Jordan CT, Pietras EM, Alper S. Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. *Haematologica*. 2019 Mar 7. [Epub ahead of print] PMID:30846499
75. Adane B, Ye H, Khan N, Pei S, Minhajuddin M, Stevens BM, Jones CL, D'Alessandro A, Reisz JA, Zaberezhnyy V, Gasparetto M, Ho TC, Kelly KK, Myers JR, Ashton JM, Siegenthaler J, Kume T, Campbell EL, **Pollyea DA**, Becker MW, Jordan CT. The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells. *Cell Rep*. 2019 Apr 2;27(1):238-254.e6. PMID:30943405
76. Medeiros BC, Chan SM, Daver NG, Jonas BA, **Pollyea DA**. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. *Am J Hematol*. 2019 Apr 3. doi: 10.1002/ajh.25484. [Epub ahead of print] PMID:30945331
77. **Pollyea DA**, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL, MacBeth KJ, Agresta SV, Attar EC, DiNardo CD, Stein EM. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. *Leukemia*. 2019 Apr 9. [Epub ahead of print] PMID: 30967620

Book Chapters and Other Media

1. **Daniel A. Pollyea**.  *Thrombocytopenia in Critically Ill Patients*. Just the Facts: Critical Care. Hall, J.B., Hogarth, D.K., Schmidt, G.A. (editors); 2006.
2. Koen van Besien, **Daniel A. Pollyea** and Andrew S. Artz. *Second Allogeneic Transplantation: Outcomes and Indications*. Allogeneic Stem Cell Transplantation: Clinical Research and Practice, 2nd Edition. Judith Karp, ed., 2008.
3. **Daniel A. Pollyea** and Jeffrey T. Schowinsky. *Atypical CML and Chronic Neutrophilic Leukemia*. Managing Myeloproliferative Neoplasms: A Case-Based Approach. Cambridge University Press (Publication pending).
4. Vignesh Narayanan and **Daniel A. Pollyea**. *Hematological Malignancies*. ENT Secrets. (Publication pending)
5. Audio Digest Internal Medicine Board Review: Hematopoetic Stem Cells and their Disorders. May 15, 2014.
6. Contiuning Medical Education Faculty, “Clinical Impact of AML Tumor Genomics.” (http://www.cmeuniversity.com/course/disclaimer/111111)

Scientific Abstracts: Oral Presentations

1. **Pollyea DA**, Kohrt HE, Gallegos L, Zhang B, Figueroa M, Melnick A, Berube C, Coutre SE, Gotlib JR, Liedtke M, Mitchell BS, Medeiros BC. Sequential Azacitidine and Lenalidomide in Elderly Acute Myeloid Leukemia: Completed Results of the Phase I Study. *American Society of Clinical Oncology Conference*, June 4-8, 2011.
2. Maxson JE, Gotlib J, **Pollyea DA**, Fleischman AG, Agarwal A, Luty SB, Abel M, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Collins RH, Pond JB, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW. The CSF3R T618I Mutation Found in Chronic Neutrophilic Leukemia Removes an O-Linked Glycosylation Site and Increases Receptor Dimerization. *American Society of Hematology Conference*, December 7-10, 2013.
3. Gutman JA, Myint H, Lee CK, Smith C, Nguyen V, **Pollyea DA**. Chronic Graft Versus Host Disease and Immunosuppression Burden is Significantly Lower Following Adult Cord Blood Transplantation Versus Matched Unrelated Donor Transplantation. *American Society for Blood and Marrow Transplantation Conference,* February 27, 2014.
4. Konopleva M, **Pollyea DA**, Potluri J, Chyla BJ, Busman T, McKeegan E, Salem A, Zhu M, Ricker JL, Blum W, DiNardo CD, Dunbar M, Kirby R, Falotico N, Leverson JD, Humerickhouse RA, Mabry M, Stone RM, Kantarjian HM, Letai AG. A Phase 2 Study of ABT-199 in Patients with Acute Myelogenous Leukemia. *American Society of Hematology Conference*, December 7, 2014.
5. Stein E, Altman JK, Collins R, DeAngelo DJ, Fathi AT, Flinn I, Frankel A, Lveine RL, Medeiros BC, Patel M, **Pollyea DA**, Roboz GJ, Sone RM, Swords RT, Tallman MS, Agresta S, Fan B, Yang H, Yen K, de Botton S. AG-221, an Oral, Selective, First-in-Class , Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies. *American Society of Hematology Conference*, December 7, 2014.
6. Riedel S, Haladyna J, Bezzant M, Stevens B, **Pollyea DA**, Sinha AU, Armstrong SA, Wei Q, Jordan CT, Neff T, Bernt KM. Targeting Meningeoma-1 Driven AML through Epigenetic Modulation of the Cell of Origin. *American Society of Hematology Conference*, December 9, 2014.
7. Stein E, Tallman M, **Pollyea DA**, Flinn IW, Fathi AT, Stone RM, Levine RL, Agresta S, Schenkein D, Yang H, Fan B, Yen K, De Botton S. Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies. *American Association for Cancer Research Conference*, April 6, 2014.
8. Agresta S, Stein EM, Tallman MS, Levine RL, Yua H, Yen K, Fan B, Flinn IW, Fathi AT, Stone RM, DeAngelo DJ, DeBotton S, **Pollyea DA**. A phase I study of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies. *European Hematology Association Conference*, June 12-15, 2014.
9. **Pollyea DA**, De Botton S, Fathi AT, Stein EM, Tallman MS, Agresta S, Bowden C, Colby K, Fan B, Goldwasser M, Prahl M, Yang H, Yen K, Stone RM. Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies. *EORTC-NCI-AACR Symposium*, November 18-21, 2014.
10. Stein EM, DiNardo C, Altman JK, Collins R, DeAngelo DJ, Kantarjian HM, Sekeres MA, Fathi AT, Flinn IW, Frankel AE, Levine RL, Medeiros BC, Patel MR, **Pollyea DA**, Roboz GJ, Stone RM, Swords RT, Tallman MS, Yen K, Attar EC, Xu Q, Tosolini A, Mei J, Thakurta A, Knight RD, De Botton S. Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. American Society of Hematology Conference, December 6, 2015.
11. DiNardo C, **Pollyea DA**, Pratz K, Thirman MJ, Letai A, Frattini M, Jonas B, Leverson J, Zhu M, Dunbar M, Falotico N, Kirby R, Agarwal S, Mabry M, Potluri J, Humerickhouse RA, Kantarjian HM, Konopleva M. A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction. American Society of Hematology Conference, December 6, 2015.
12. Riedel S, Haladyna J, Stevens B, Jordan CT, **Pollyea DA**, Armstrong SA, Wei Q, Ernst P, Neff T, Bernt KM. Meningeoma-1 Cooperates with MLL and DOT1L to Induce Leukemia. American Society of Hematology Conference, December 6, 2015.
13. Pei S, Minhajuddin M, Stevens BM, Adane B, Khan N, D'alessandro A, Nemkov T, Hansen KC, **Pollyea DA**, Jordan CT. Regulation of Mitochondrial Morphology Is Important for Leukemia Stem Cell Function. American Society of Hematology Conference, December 7, 2015.
14. DiNardo CD, de Botton S, SteinEM, RobozGJ, Swords RT, **Pollyea DA**, Fathi AT, CollinsR, Altman JK, Flinn IW, MannisGN, Mims AS, Foran JM, Pigneux A, Prince GT, Uy GL, Tallman MS, Kantarjian HM, Liu H, Attar EC, Sacolick J, YenK, HurovJB, Choe S, WuB and Stone RM. Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1. American Society of Hematology Conference, December 5, 2016.
15. Stein EM, Fathi AT, DiNardo CD, **Pollyea DA**, Swords RT, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Tosolini A, Xu Q, Amatangelo M, Gupta I, Knight RD, De Botton S, Tallman MS, Kantarjian HM. Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (*IDH2*) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes. American Society of Hematology Conference, December 4, 2016.
16. Stein EM, DiNardo CD, **Pollyea DA**, Fathi AT, Roboz GJ, Altman JK, Stone RM, Flinn IW, Kantarjian HM, Collins R, Patel MR, Stein A, Sekeres NA, Swords RT, Medeiros BC, Knight RD, Agresta S, de Botton S, Tallman MS. Enasidenib (AG0221) in mutant IDH2 relapsed or refractory acute myeloid leukemia: Results of a phse 1 dose escalation and expansion study. European Hematology Association annual meeting, June 23, 2017.
17. Pratz K, **Pollyea DA**, Jonas BA, Pullarkat V, Wei A, Arellano M, Becker PS, Frankfurt O, Thirman M, Pigneux A, Recher C, Seymour JF, Dvorak N, Xu T, Humerickhouse R, Mabry M, Potluri J, Letai A, DiNardo C. Safety and efficacy of venetoclax in combination with decitabine or azacitidine in treatment naïve, elderly patients with AML. European Hematology Association annual meeting, June 24, 2017.
18. George TI, Foucar K, **Pollyea DA**, Erba HP, Thompson MA, Roboz GJ, Pagel JM, Cogle CR, Nifenecker M, Swern AS, Kiselev P, Sugrue MM. Antecedent Conformity of Diagnostic and Molecular Testing Patterns in Clinical Practice for Newly Diagnosed Acute Myeloid Leukemia With American Society of Hematology and College of American Pathologists Guidelines. American Society for Clinical Pathology annual meeting, September 7, 2017.
19. DiNardo CD, De Botton S, Stein EM, Roboz GJ, Mims AS, **Pollyea DA**, Swords R, Altman JK, Collins RH, Mannis GN, Uy GL, Donnellan W, Pigneux A, Fathi AT, Stein AS, Erba HP, Prince GT, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Yen K, Kapsalis SM, Liu H, Goldwasser M, Agresta S, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Ivosidenib (AG-120) in mutant IDH1 AML and advanced hematologic malignancies: results of a phase 1 dose escalation and expansion study. American Society of Hematology Conference, December 11, 2017.
20. Stein EM, DiNardo CD, Mims AS, Savona MR, Pratz K, Stein AS, Fathi AT, Stone RM, **Pollyea DA**, Odenike O, Löwenberg R, Döhner H, Schiller G, Gupta IV, Nabhan S, Zhang V, Almon C, Cooper M, Tallman MS. Ivosidenib or enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 mutation: initial results from a phase 1 trial. American Society of Hematology Annual Meeting, December 11, 2017.
21. Daver N, **Pollyea DA**, Yee KWL, Fenaux P, Brandwein JM, Vey N, Martinelli G, Kelly KR, Roboz GJ, Garcia JS1, Pigneux A, Kshirsagar S, Dail M, Wang J, Mobasher M, Chen L, Hong W, Konopleva M, Andreeff M. Preliminary results from a phase 1b study evaluating BCL-2 inhibitor venetoclax in combination with MEK inhibitor cobimetinib or MDM2 inhibitor idasanutlin in patients with relapsed or refractory AML. American Society of Hematology Annual Meeting, December 11, 2017.
22. **Pollyea DA**, Tallman MS, De Botton S, DiNardo CD, Kantarjian HM, Collins RH, Stein AS, Xu Q, Tosolini A, Gupta I, Agresta SV, Stein EM. Enasidenib monotherapy is effective and well-tolerated in patients with previously untreated mutant IDH2 AML. American Society of Hematology Annual Meeting, December 11, 2017.
23. **Pollyea DA**, Stevens BM, Winters A, Minhajuddin M, Gutman JA, Purev E, Smith C, Abbott D, Jordan CT. Venetoclax with azacitidine for untreated elderly AML patients unfit for induction chemotherapy: single center clinical experience and mechanistic insights from correlative studies. American Society of Hematology Annual Meeting, December 11, 2017.
24. de Botton S, Stein EM, Stone RM, **Pollyea DA**, Roboz GJ, Altman JK, DiNardo CD, Tu N, Swern AS, Tosolini A, Gupta I, Agresta SV, Fathi AT. Continuing enasidenib treatment for patients with mutant IDH2 relapsed or refractory AML with stable disease may result in improved survival and responses over time.  Societe Francaise d'Hematologie Annual Meeting, March 28, 2018, Paris.
25. Pratz K, **Pollyea DA**, Jonas B, Pullarkat V, Wei A, Arellano M, Becker P, Frankfurt O, Thirman M, Pigneux A, Recher C, Seymour J, Dvorak N, Xu T, Humerickhouse R, Mabry M, Potluri J, Letai A, DiNardo C. Safety and efficacy of venetoclax in combination with decitabine or azacitidine in treatment-naïve, elderly patients >65 years with acute myeloid leukemia. *British Society of Hematology Annual Meeting*, April 16-18, Liverpool UK.
26. **Pollyea, DA**, Dinardo CD, de Botton S, Stein E, Roboz GJ, Mims AS, Swords RT, Altman JK, Collins R, Mannis GN, Uy GL, Donnellan WB, Pigneus A, Fathi AT, Liu H, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Ivosidenib in mutant IDH1 relapsed/refractory acute myeloid leukemia: results of a phase 1 study. American Society of Clinical Oncology meeting, Chicago June 2, 2018.
27. Dinardo CD, Pratz KW, Potluri J, Pullarkat VA, Jonas BA, Wei AH, Becker PS, Frankfurt O, Xu T, Hong W, Chyla B, **Pollyea DA**, Letai AG. Durable response with venetoclax in combination with decitabine or azacitidine in elderly patients with acute myeloid leukemia. American Society of Clinical Oncology Meeting, Chicago June 4, 2018.
28. **Pollyea, DA**, Dinardo CD, de Botton S, Stein E, Roboz GJ, Mims AS, Swords RT, Altman JK, Collins R, Mannis GN, Uy GL, Donnellan WB, Pigneus A, Fathi AT, Liu H, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Ivosidenib in mutant IDH1 relapsed/refractory acute myeloid leukemia: results of a phase 1 study. European Hematology Association meeting, Stockholm, June 17, 2018.
29. **Pollyea, DA,** Tallman M, de Botton S, DiNardo CD, Kantarjian H, Collins R, Stein AS, Xu Q, Tosolini A, vdn Oostendorp J, Agresta SV, Stein EM. Enasidenib monotherapy is effective and well tolerated in patients with previously untreated mutant IDH2 AML. European Hematology Association meeting, Stockholm, June 17, 2018.
30. Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan WB, Erba HP, Mannis GN, **Pollyea DA**, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman mS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM. Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study. American Society of Hematology meeting, San Diego, December 3, 2018.
31. Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döhner H, **Pollyea DA**, McCloskey JK, Odenike O, Löwenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Lersch F, Nabhan S, Choe S, Wang H, Hua L, Almon C, Cooper M, Tallman M S. Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions. American Society of Hematology meeting, San Diego, December 3, 2018.
32. Daver NG**, Pollyea DA**, Garcia JS, Jonas BA, Yee KWL, Fenaux P, Assouline S, Vey N, Olin R, Roboz GJ, Tafuri A, Visani G, Kirschbrown W, Green, Ma C, Dail M, Wang J, Ott MG, Mobasher M, Phuong P, Hong W, Konopleva MY, Andreeff M. Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. American Society of Hematology meeting, San Diego, December 3, 2018.
33. **Pollyea DA**, Pratz KW, Jonas BA, Letai A, Pullarkat VA, Wei A, Konopleva MY, Recher C, Frankfurt O, Rizzieri D, Xu T, Dail M, Chyla B, Potluri J, DiNardo CD. Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy. American Society of Hematology meeting, San Diego, December 2, 2018.
34. Jones CL, Stevens BM, D'Alessandro A, Reisz J, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Reinhold D, Smith C, DeGregori J, **Pollyea DA**, Jordan CT. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. American Society of Hematology meeting, San Diego, December 1, 2018.
35. Gerds AT, Scott BL, Greenberg PL, Khaled SK, Lin TL, **Pollyea DA**, Verma A, Dail M, Green C, Ma C, Medeiros BC, Phuong P, Wenger M, Yan M, Donnellan WB. PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis. American Society of Hematology meeting, San Diego, December 2, 2018.
36. **Pollyea DA**, Jones CL, Stevens BM, Pei S, D'Alessandro A, Culp-Hill R, Abbott D, Hammes A, Dugan J, Gutman JA, Purev E, Smith C Jordan CT. Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1. American Society of Hematology meeting, San Diego, December 2, 2018.
37. Stevens BM, Jones CL, Winters A, Dugan J, Abbott D, Savona MR, Fesik SW, **Pollyea DA**, Jordan CT. PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia. American Society of Hematology meeting, San Diego, December 3, 2018.
38. Jones CL, Stevens BM, Culp-Hill R, Nemkov T, D'Alessandro A, Pei S, **Pollyea DA**, Jordan CT. Leukemia Stem Cells in Relapsed AML Patients Are Uniquely Dependent on Nicotinamide Metabolism. American Society of Hematology meeting, San Diego, December 2, 2018.
39. Ye H, Adane B, Khan N, Minhajuddin M, Stevens BM, A Pollyea DA, Jordan CT. Subversion of Systemic Glucose Metabolism As a Mechanism to Support the Growth of Leukemia Cells. American Society of Hematology meeting, San Diego, December 3, 2018.

Scientific Abstracts: Poster Presentations

1. Pollyea D, Kim E, Manley C, McCrudden K, Huang J, Yokoi A, Soffer S, Kandel J, and Yamashiro D. TNP-470 Alters but does not inhibit angiogenesis in neuroblastoma. *Proceedings of the Pediatric Academic Society Conference*, April 28-May 1, 2001.
2. **Pollyea D**. Pulse-pancreatitis: A diagnosis of exclusion. *American College of Physicians Annual Associates Meeting*, September 4-5, 2003.
3. **Pollyea D, Artz A, Stock W, Smith S, Daugherty C, Godley L, Zimmerman T, Odenike O, Thirman M, Rich E, Larson R, Van Besien K. Clinical predictors of transplant related mortality after reduced intensity allogeneic stem cell transplantation (RIST). *American Society of Hematology Conference*, December 4-7, 2004.**
4. **Kline J, Pollyea D, Artz A, Stock W, Rich E, Godley L, Zimmerman T, Van Besien K. Ganciclovir and high-dose valacyclovir reduce cytomegalovirus reactivation in patients receiving allogeneic stem cell transplantation with Campath-1 H based conditioning regimens. *Tandem Bone Marrow Transplant Meetings*, February 10-14, 2005.**
5. **Pollyea DA, Artz AS, Kocherginsky M, Stock W, Smith SM, Daugherty C, Godley L, Zimmerman T, Odenike OM, Thirman M, Rich E, Larson R, Van Besien K. Clinical predictors of transplant related mortality after reduced intensity allogeneic stem cell transplantation. *European Hematology Association 10th Congress*, June 2-5, 2005.**
6. **Pollyea D, Artz A, Stock W, Godley L, Odenike O, Rich E, Smith S, Larson R, Van Besien K. Leukemic relapse after allogeneic stem cell transplantation with a T-cell depleted reduced intensity conditioning (RIST) regimen. *American Society of Hematology Conference*, December 10-13, 2005.**
7. **Michaelis LC, Joseph L, Lin SP, Kline J, Artz A, Pollyea D, Stock W, Rich E, Jones D, Casey B, Van Besien K. Donor chimerism after reduced-intensity allogeneic transplantation for hematologic malignancies and relationship to clinical outcomes. *Tandem Bone Marrow Transplant Meetings,* February 16-20, 2006.**
8. **Pollyea D,** Artz A, Stock W, Daugherty C, Godley L, Odenike O, Rich E, Smith S, Zimmerman T, Zhang Y, Huo D, Larson R, Van Besien K. New Cytogenetic Abnormalities are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation. *American Society of Hematology Conference*, December 9-12, 2006.
9. Dinner S, Artz A, Kocherginsky M, Ulaszek J, **Pollyea D**, Godley L, Larson R, Odenike O, Rich E, Stock W, Van Besien K, Wickrema A. **Biomarkers To Predict Outcome after Allogeneic Hematopoietic Cell Transplant (HCT). *American Society of Hematology Conference*, December 8-11, 2007.**
10. **Pollyea D**, Smith S, Fowler N, Boyd T, Smith A, Sirisawad M, Honigberg L, Hamdy A, Advani R. A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. *American Society of Hematology Conference*, December 4-8, 2009.
11. Advani R, Sharman JP, Smith SM, **Pollyea DA**, Boyd TE, Grant BW, Kolibaba KS, Buggy JJ, Hamdy A, Fowler NH. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. *American Society of Clinical Oncology Conference*, June 4-8, 2010.
12. Raval A, **Pollyea DA**, Shridhar KJ, Patel S, Greenberg PL, Mitchell BS. Ribosomal RNA Expression in CD34+ Hematopoietic Progenitor Cells Inversely Correlates With Ribosomal DNA Methylation in Myelodysplastic Syndromes. *American Society of Hematology Conference*, December 4-7, 2010.
13. **Pollyea DA**, Raval A, Kusler B, Gotlib JR, Alizadeh AA, Mitchell BS. A Novel Missense Mutation in an MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes. *American Society of Hematology Conference*, December 4-7, 2010.
14. **Pollyea DA**, Kohrt HE, Gallegos L, Berube C, Coutre S, Gotlib JR, Liedtke M, Mitchell BS, Medeiros BC. A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia. *American Society of Hematology Conference*, December 4-7, 2010.
15. **Pollyea DA**, Kohrt HE, Rajwanshi R, Gallegos L, Berube C, Coutre S, Gotlib JR, Liedtke M, Mitchell BS, Medeiros BC. An Early Phase Study of Azacitidine and Lenalidomide for Untreated Elderly Acute Myeloid Leukemia Patients. *American Society of Clinical Oncology Conference*, June 4-8, 2010.
16. **Pollyea DA**, Kohrt HE, Zhang B, Zehnder J, Schenkein D, Fantin V, Straley K, Godley L, Medeiros BC. 2-Hydroxyglutarate in *IDH* Mutant AML Patients: Predicting Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels. *American Society of Hematology Conference,* December 10-13, 2011.
17. **Pollyea DA**, Zehnder J, Coutre S, Gotlib JR, Gallegos L, Abdel-Wahab O, Greenberg P, Zhang B, Liedtke M, Berube C, Levine R, MitchellBS and MedeirosBC. Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy. *American Society of Hematology Conference*, December 8-11, 2012.
18. **Pollyea DA**, Kohrt HE, Yang J, Chang ET, Gomez SL, Clarke CA. Acute Leukemia in Hispanic Americans: Incidence and Incidence Rate Differences by Nativity. *American Society of Hematology Conference*, December 8-11, 2012.
19. **Pollyea DA,** Gore L, Gutman J, Eckhardt SG, Hagelstrom N, Coutre S, Thirman M, Byrd J. A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. *Targeted Anticancer Therapy Conference*, March 4-6, 2013. Paris, France.
20. Gasparetto M, Jordan CT, Minhajuddin M, **Pollyea DA**, Vasilou V, Reigan P, Humphries RK, Smith CA. ALDH Genes and Reactive Aldehydes Play Important Roles in HSCs and Leukemia and May be Exploited to Treat AML. *American Society of Hematology Conference*, December 7-10, 2013.
21. **Pollyea DA**, Coutre S, Gore L, Adler N, Harris P, Phelps MA, Johnson AJ, Ling Y, Li H, Gutman JA, Byrd JC. A Dose Escalation Study of Ibrutinib for Relapsed and Refracotry Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. *American Society of Hematology Conference*, December 6, 2014.
22. **Pollyea DA**, Smith CA, Nguyen VH, Fullerton A, Schatz D, Bedrick EJ, Gutman JA. Sequential Azacitidine and High-Dose Lenalidomide for Relapsed and Refractory High-Risk MDS and AML: Interim Analysis of a Phase 2 Study. *American Society of Hematology Conference*, December 8, 2014.
23. Gasparetto M, Pei S, Minhajuddin M, **Pollyea DA**, Vasiliou V, Humphries RK, Jordan CT, Smith CA. Aldehyde Dehydrogenases Play a Role in Acute Myeloid Leukemia and Have Prognostic and Therapeutic Significance. *American Society of Hematology Conference*, December 7, 2014.
24. Steensma DP, Abedi M, Attar EC, Bejar R, Cogle CR, Garcia-Manero G, Grinblatt DL, Ma X, Maciejewski JP, **Pollyea DA**, Roboz GJ, Savona M, Scott BL, Sekeres MA, Thompson MA, Zernovak O, Sugrue MM, Swern AS, Nifenecker M, Erba HP. Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry. *American Society of Clinical Oncology Conference*, May 30-June 3, 2014.
25. Cortes J, O’Connell A, Shaik MN, Cesari R, Abbattista A, Woolfson A, **Pollyea DA**, Savona M. Phase IB study of PF-04449913, a hedgehog inhibitor, in combination with low-dose cytarabine or intensive chemotherapy, in AML or high-risk MDS. *European Hematology Association Conference*, June 12-15, 2014.
26. Gutman JA, Denoncourt E, Schatz D, Smith C, **Pollyea DA**. A Phase 2 Study of the Hedgehog Pathway Smoothened Inhibitor PF-04449913 to Reduce Relapse in High Risk Acute Leukemia and MDS Patients Following Allogeneic Transplantation. *American Society for Blood and Marrow Transplantation*, February 11-15, 2015.
27. Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Maciejewski J, **Pollyea DA**, Roboz GJ, Savona M, Scott B, Sekeres M, Thompson MA, Sugrue MM, Swern AS, Nifenecker M, Erba H MD. ConnectMDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. *The 13th International Symposium on Myelodysplastic Syndromes*, April 29-May 2, 2015.
28. DiNardo C, de Botton, **Pollyea DA**, Stein EM, Fathi AT, Roboz GJ, Collins R, Swords RT, Flinn IW, Altman JK, Tallman MS, Kantarjian HM, Derti A, Goldwasser M, Prahl M, Wu B, Yen K, Agresta S, Stone RM. Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study. *American Society of Hematology Conference*, December 5, 2015.
29. Nooruddin Z, Robinson W, **Pollyea DA**, Gutman JA, Smith C, Pan Z, Jordan CT, Rabinovitch R, Schowinsky J, Lu X, Ney D, Kamdar M. IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A Single Center Experience. *American Society of Hematology Conference,* December 5, 2015.
30. Stevens BM, **Pollyea DA**, Khan N, Jordan CT. Characterization and Targeting of Myelodysplastic Syndrome Stem Cells. *American Society of Hematology Conference*, December 7, 2015.
31. **Pollyea DA**, Dinardo CD, Thirman MJ, Letai A, Wei AH, Jonas BA, Arellano ML, Frattini MG, Kantarjian HM, Chyla B, Zhu M, Potluri J, Humerickhouse R, Mabry MH, Konopleva M, Pratz KW. Results of a Phase 1b Study of Venetoclax Plus Decitabine or Azacitidine in Untreated Acute Myeloid Leukemia Patients ≥ 65 Years Ineligible for Standard Induction Therapy. *American Society of Clinical Oncology Conference*, June 6, 2016.
32. **Pollyea DA**, Dinardo CD, Thirman MJ, Letai A, Wei AH, Jonas BA, Arellano ML, Frattini MG, Kantarjian HM, Chyla B, Zhu M, Potluri J, Humerickhouse R, Mabry MH, Konopleva M, Pratz KW. Results of a Phase 1b Study of Venetoclax Plus Decitabine or Azacitidine in Untreated Acute Myeloid Leukemia Patients ≥ 65 Years Ineligible for Standard Induction Therapy. *European Hematology Association Conference*, June 10, 2016.
33. George TI, Erba HP, Steensma DP, **Pollyea DA**, Abedi M, Bejar R, Cogle CR, Garcia-Manero G, Grinblatt DL, Komrokji RS, Maciejewski JP, Revicki D, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Thompson MA, Fliss A, Swern AS, Nifenecker M, Kiselev P, Sugrue MM, Foucar K. Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT® Myelodysplastic Syndromes (MDS) and AML Disease Registry. American Society of Hematology Conference, December 4, 2016.
34. Nooruddin Z, Pan Z, Gross L, Weitzenkamp D, Haverkos BM, **Pollyea DA**, Gutman JA, Robinson W, Smith C, Schowinsky J, Purev E, Sherbenou DW, Rabinovitch R, Ney D, Jordan CT, Kamdar M. Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes. American Society of Hematology Conference, December 4, 2016.
35. Pei S, Minhajuddin M, Adane B, Stevens BM, Khan N, D'alessandro A, Nemkov T, Hansen KC, **Pollyea DA**, Jordan CT. Mitochondrial Fission 1 Regulates GSK3 and AMPK Signaling to Sustain Leukemia Stem Cell Function in Acute Myelogenous Leukemia. American Society of Hematology Conference, December 3, 2016.
36. Adane B, Ye H, Pei S, Khan N, Minhajuddin M, Stevens BM, Zaberezhnyy V, **Pollyea DA**, Jordan CT. The Role of NADPH Oxidase 2 in Normal and Malignant Hematopoiesis. American Society of Hematology Conference, December 5, 2016.
37. Stevens BM, **Pollyea DA**, Khan N, Jordan CT. Distinct Metabolic Properties of MDS Stem Cells Provide Novel Opportunities for Therapeutic Intervention. American Society of Hematology Conference, December 5, 2016.
38. George TI, Erba HP, **Pollyea, DA**, Abedi M, Roboz GJ, Thompson, MA, Fliss A, Swern AS, Nifenecker M, Kiselev P, Sugrue MM, Foucar K. Current diagnosis patterns for acute myeloid leukemia: Concordance between clinical practice (CONNECT Disease Registry) and WHO 2008 recommendations. 14th International Symposium on Myelodysplastic Syndromes, May 4, 2017.
39. **Pollyea DA**, George TI, Foucar K, Erba HP, Thompson MA, Abedi M, Roboz GJ, Landau DA, Pagel JM, Seiter K, Cogle CR, Nifenecker M, Swern AS, Kiselev P, Sugrue MM. Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia enrolled in the CONNECT MDS/AML disease registry. American Society of Clinical Oncology, June 5, 2017.
40. **Pollyea DA**, George TI, Foucar K, Erba HP, Thompson MA, Abedi M, Roboz GJ, Landau DA, Pagel JM, Seiter K, Cogle CR, Nifenecker M, Swern AS, Kiselev P, Sugrue MM. Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia enrolled in the CONNECT MDS/AML disease registry. European Hematology Association annual meeting, June 23, 2017.
41. Cortes JE, Smith BD, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, **Pollyea DA**, Ma Weidong, Zeremski M, Shaik MN, O’Connell A, Chan G, Schroder MA. A phase 2 study of glasdegib (PF-04449913) in combination with cytarabine and daunorubicin in untreated patients with AML or high-risk MDS. European Hematology Association annual meeting, June 10, 2017. European Hematology Association annual meeting, June 23, 2017.
42. Drusbosky LM, Hawkins KE, Leather HL, Murthy HS, Farhadfar N, Wingard JR, Norkin M, Brown RA, Hiemenz JW, Castillo P, Horn BN, Kumar A, Singh NK, Kumar C, Vasista S, Abbasi T, Vali S, Tognon CE, Kurtz SE, Druker BJ, Tyner JW, **Pollyea DA,** Cogle CR. A genomic signature predicting venetoclax treatment response in AML identified by protein network mapping and validated by ex vivo drug sensitivity testing. American Society of Hematology Annual Meeting, December 10, 2017.
43. Daver N, **Pollyea DA**, Rizzieri DA, Palmer J, Rampal RK, Dinner S, Bixby DL, Percival MM, Kovacsovics T, Begna KH, Perl AE, Konopleva M, Seitz L, McKinnell J, Johnson DT, Ho W, Cortes JE. A phase 1 study of FLX925, a dual FLT3 and CDK4/6 inhibitor in patients with relapsed or refractory AML. American Society of Hematology Annual Meeting, December 9, 2017.
44. DiNardo CD, **Pollyea DA**, Jonas BA, Konopleva M, Pullarkat V, Wei A, Kantarjian HM, Pigneux A, Recher C, Seymour JF, Dunbar M, Xu T, Mabry M, Potluri J, Pratz K, Letai A. Updated safety and efficacy of venetoclax with decitabine or azacitidine in treatment naïve, elderly patients with AML. American Society of Hematology Annual Meeting, December 10, 2017.
45. Stevens BM, Winters A, Gutman JA, Fullerton A, Hemenway G, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, TechB, Drusbosky LM, Cogle CR, Hammes A, Jordan CT, **Pollyea DA**. Sequential azacitidine and lenalidomide for patients with relapsed and refractory AML: clinical results and predictive modeling using computational analysis and serial genomics. American Society of Hematology Annual Meeting, December 9, 2017.
46. Stein EM, Stone RM, **Pollyea DA**, Roboz GJ, Altman JK, DiNardo CD, de Botton S, Tu N, Swern AS, Tosolini A, Gupta I, Agresta SV, Fathi AT. Continuing enasidenib treatment for patients with mutant IDH2 relapsed or refractory AML with stable disease may result in improved survival and responses over time. American Society of Hematology Annual Meeting, December 9, 2017.
47. Cogle CR, **Pollyea DA**, Abedi M, Thompson MA, Roboz GJ, Louis CU, Flick ED, Nifenecker M, Kiselev P, Swern AS, Erba HP. Factors influencing first line therapy of AML patients in the Connect MDS/AML disease registry. American Society of Clinical Oncology, June 4, 2018.
48. Fong CY, Wei AH, Frattini M, Jacoby M, Borate U, Gotze K, Carcia JS, **Pollyea DA**, Holes L, Zhou Y, Fakouhi K, Lverson J, Harb JG, Agarwal SK, Attarchi F, Hong W, Jahn TM, Fenaux P, Garcia-Manero G. Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher risk myelodysplastic syndromes. American Society of Clinical Oncology Meeting, June 4, 2018.
49. Stein EM, Stone RM, **Pollyea DA**, Roboz GJ, Altman JK, DiNardo CD, de Botton S, Tu N, Swern AS, Tosolini A, Gupta I, Agresta SV, Fathi AT. Continuing enasidenib treatment for patients with mutant IDH2 relapsed or refractory AML with stable disease may result in improved survival and responses over time. European Hematology Association, Stockholm, Sweden, June 16, 2018.
50. Strickland SA, Chyla B, Popovic R, Bhathena A, Dail M, Sun Y, Wei AH, Fiedler W, Prtaz K, Hayslip J, Potluri J, DiNardo CD, **Pollyea DA**. Cytogenetic and molecular drivers of outcome with venetoclax based combination therapies in treatment naïve elderly patients with AML. European Hematology Association, Stockholm, Sweden, June 16, 2018.
51. Cortes JE, Heidel F, Fiedler W, Smith BD, Robak T, Fernandez P, Candoni A, Leber B, Sekeres MA, **Pollyea DA**, Zeremski M, Ma W, O’Brien T, O’Connell A, Chan G, Heuser M. Glasdegib improved overall survival in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who achieved complete remission (CR) and those who did not achieve CR. European Hematology Association, Stockholm, Sweden, June 16, 2018.
52. Strickland SA, Chyla B, Popovic R, Bhathena A, Dail M, Sun Y, Wei AH, Fiedler W, Prtaz K, Hayslip J, Potluri J, DiNardo CD, **Pollyea DA**. Cytogenetic and molecular drivers of outcome with venetoclax based combination therapies in treatment naïve elderly patients with AML. Uruguayan Congress of Hematology, Montevideo, Uruguay, October 19, 2018.
53. Mukherjee S, Abedi M, Erba HP, **Pollyea DA**, Roboz GJ, Thompson MA, Louis CU, Flick ED, Nifenecker M, Kiselev P, Swern AS, Cogle CR. Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect MDS/AML Disease Registry. American Society of Hematology annual meeting, December 3, 2018.
54. Stevens BM, Winters A, Abbasi T, Singh NK, Ullal YS, Kumari I, Tyagi A, Alam A, Lunkad N, Drusbosky LM, Cogle CR, Vali S, **Pollyea DA**. WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML). American Society of Hematology annual meeting, San Diego, CA. December 1, 2018.
55. Jones CL, Stevens BM, D'Alessandro A, Culp-Hill R, Reisz J, Ye H, Khan N, Minhajuddin M, DeGregori J, **Pollyea DA**, Jordan CT. Cysteine and Cystine Depletion Targets Leukemia Stem Cells. American Society of Hematology annual meeting, San Diego, CA. December 2, 2018.
56. Cortes JE, Merchant A, Jamieson C, **Pollyea DA**, Heuser M, Chan G, Wang P, Ching KA, 7, Johnson JA, O'Brien T. Biomarkers of Overall Survival and Response to Glasdegib and Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia. American Society of Hematology annual meeting, San Diego, CA. December 2, 2018.
57. Sharma P, Purev E, Haverkos BM, **Pollyea DA**, Smith C, Kamdar M, Sherbenou DW, Mark TM, Forsberg PA, Gutman JA. Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation. American Society of Hematology annual meeting, San Diego, CA. December 3, 2018.
58. Winters A, Goosman M, Stevens BM, Purev E, Smith C, Pollyea DA, Jordan CT, Gutman JA. Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant. American Society of Hematology annual meeting, San Diego, CA. December 1, 2018.
59. Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Swords RT, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, Tosloini A, Zu Q, See WL, MacBeth KJ, de Botton S, Tallman MS, Kantarjian HM. Enasidienib induces durable hematologic responses in patients with mutant IDH2 myelodysplastic syndromes. International Symposium on MDS, Copenhagen, Denmark. May 11, 2019.